Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$774M |
| 2 |
Intuitive Surgical
ISRG
|
+$654M |
| 3 |
S&P Global
SPGI
|
+$464M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$326M |
| 5 |
CELG
Celgene Corp
CELG
|
+$243M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FedEx
FDX
|
+$591M |
| 2 |
Broadcom
AVGO
|
+$550M |
| 3 |
Monster Beverage
MNST
|
+$408M |
| 4 |
Booking.com
BKNG
|
+$377M |
| 5 |
McDonald's
MCD
|
+$371M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.27% |
| 2 | Consumer Discretionary | 16.23% |
| 3 | Healthcare | 15.49% |
| 4 | Financials | 12.97% |
| 5 | Communication Services | 11.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Eaton
ETN
$156B
| $12.5M | 0.01% |
144,458
-143,984
| -50% | -$11.8M |
|
452
Alcoa
AA
$11.9B
| $12.2M | 0.01% |
300,764
-18,258
| -6% | -$793K |
|
|
WBT
453
DELISTED
Welbilt, Inc.
WBT
| $12.1M | 0.01% |
579,878
+549,255
| +1,794% | +$12.1M |
|
|
NFX
454
DELISTED
Newfield Exploration
NFX
| $12M | 0.01% |
416,957
+18,137
| +5% | +$510K |
|
|
EVBG
455
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $11.9M | 0.01% |
205,627
+1,605
| +0.8% | +$86.6K |
|
|
AIMT
456
DELISTED
Aimmune Therapeutics
AIMT
| $11.8M | 0.01% |
432,976
+3,442
| +0.8% | +$97.4K |
|
|
ANDX
457
DELISTED
Andeavor Logistics LP
ANDX
| $11.8M | 0.01% |
242,866
+9,348
| +4% | +$439K |
|
458
AT&T
T
$159B
| $11.7M | 0.01% |
460,085
-33
| -0% | -$808 |
|
459
Repligen
RGEN
$7.91B
| $11.6M | 0.01% |
208,690
+1,886
| +0.9% | +$97.2K |
|
460
Chemours
CC
$2.46B
| $11.6M | 0.01% |
292,943
-41,236
| -12% | -$1.8M |
|
|
RUBY
461
DELISTED
Rubius Therapeutics, Inc
RUBY
| $11.3M | 0.01% |
+472,209
| New | +$10.8M |
|
462
Dorman Products
DORM
$4B
| $11.1M | 0.01% |
144,575
+137,118
| +1,839% | +$10.5M |
|
|
IMGN
463
DELISTED
Immunogen Inc
IMGN
| $11.1M | 0.01% |
1,173,360
+8,717
| +0.7% | +$83.8K |
|
464
iRhythm Holdings
IRTC
$3.87B
| $10.8M | 0.01% |
114,451
-2,848
| -2% | -$248K |
|
|
CIM
465
Chimera Investment
CIM
$1.04B
| $10.8M | 0.01% |
198,143
-3,289
| -2% | -$185K |
|
466
Western Midstream Partners
WES
$19B
| $10.7M | 0.01% |
358,533
-125,410
| -26% | -$4.4M |
|
467
Sunrun
RUN
$2.3B
| $10.6M | 0.01% |
854,041
-56,801
| -6% | -$786K |
|
|
APLS
468
DELISTED
Apellis Pharmaceuticals
APLS
| $10.2M | 0.01% |
574,859
+4,395
| +0.8% | +$81.2K |
|
469
Charter Communications
CHTR
$17B
| $10.1M | 0.01% |
30,947
-243,567
| -89% | -$74.3M |
|
|
SEI
470
Solaris Energy Infrastructure
SEI
$3.21B
| $9.99M | 0.01% |
528,745
-54,343
| -9% | -$872K |
|
471
AnaptysBio
ANAB
$1.56B
| $9.84M | 0.01% |
+98,593
| New | +$8.18M |
|
472
Philips
PHG
$25.4B
| $9.8M | 0.01% |
277,486
-126,845
| -31% | -$4.34M |
|
473
Keurig Dr Pepper
KDP
$42.7B
| $9.52M | 0.01% |
410,856
-179,685
| -30% | -$5.68M |
|
474
Viking Therapeutics
VKTX
$3.75B
| $9.5M | 0.01% |
+545,400
| New | +$6.49M |
|
|
CWEN.A
475
DELISTED
Clearway Energy Class A
CWEN.A
| $9.49M | 0.01% |
498,335
-8,271
| -2% | -$157K |
|
Similar funds
Jennison Associates's Q3 2018 Portfolio in Review
As of Q3 2018, Jennison Associates held 739 positions worth $109B, up 5.9% from $103B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Jennison Associates's Q3 2018 filing shows 86 new, 214 increased, 352 reduced and 81 closed positions. Its largest new stake was Tiffany & Co.: 1,169,094 shares worth $151M. The largest sale was FedEx, an estimated $591M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Jennison Associates's largest Q3 2018 buy was Tiffany & Co.: 1,169,094 shares worth $151M.
- Jennison Associates added most to AstraZeneca in Q3 2018, an estimated $774M increase.
- Jennison Associates's biggest Q3 2018 reduction was FedEx, cutting an estimated $591M.
- Jennison Associates fully exited Cheniere Energy Partners LP Holdings LLC in Q3 2018, selling an estimated $134M.
- Jennison Associates's ten largest holdings make up 30% of its $109B portfolio in Q3 2018.
- Jennison Associates opened 86 new positions and closed 81 in Q3 2018.
- Jennison Associates's portfolio value rose 5.9% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q3 2018, filed 8 Nov 2018.